Grant of Options

BiVictriX Therapeutics PLC

13 August 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

Grant of Options

PDMR/Director Dealings

Alderley Park, 13 August 2024 - BiVictriX Therapeutics plc (AIM: BVX), a drug discovery and development company applying an innovative, proprietary approach to develop a new class of highly selective, next generation cancer therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency, whilst reducing treatment-related toxicities, announces a grant of options over an aggregate of 2,717,776 ordinary shares of 1 pence each in the capital of the Company (the "Options") to certain Directors/PDMRs of the Company.

The Options have an exercise price of 13 pence each, and will either vest over three years, or be subject to the achievement of strategic corporate and financial goals that the Board believes will create value for Shareholders. The Options will expire ten years from the date of grant.

The Options have been awarded upon the recommendation of the Company's Remuneration Committee and pursuant to the terms of the Company's Share Option Plan, which was updated and adopted on 28 March 2024.

As part of this review and grant of Options, 1,032,667 of Tiffany Thorn's previously awarded options, which were awarded at the time of the IPO in August 2021, and were aligned to performance criteria, have subsequently been cancelled due to the performance conditions assigned to them no longer being regarded as appropriate for the business.

 The following Options have been granted to Directors/PDMRs of the Company:

Director/PDMR	New Options granted	Options Cancelled	Total Options held
Tiffany Thorn	2,197,776	1,032,667	6,862,109
Susan Lowther	200,000	-	200,000
Oliver Schon	320,000	-	1,136,333

Following this grant of Options, the total number of ordinary shares under option is 11,113,443, representing 13.5 per cent. of the Company's total issued share capital.

ENDS

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Michael Kauffman, Non-Executive Chairman  Email:  [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker)   Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Liberum Limited (Joint Broker)   Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl ICR Consilium Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe Tel: [phone] Email:  [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at  www.bivictrix.com   

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1)   Tiffany Thorn 2)   Susan Lowther   3)   Oliver Schon
2.	Reason for the Notification
a)	Position/status	1)    CEO 2)    Non-Executive Director 3)    VP, R&D
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	BiVictriX Therapeutics plc
b)	LEI	213800ZI85IZNA6N3L53
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1 pence each GB00BNXH3K91
	Identification code
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)	All Options have an exercise price of 13 pence each Volume of Options 1 )    2,197,776 2)    200,000 3)   320,000
d)	Aggregated information: -   Aggregated volume -   Price	Volume:  2,717,776 Options Exercise price of all Options: 13 pence each
e)	Date of the transaction	13 August 2024
f)	Place of the transaction	Outside a trading venue

 

END